Nuvalent Inc. has disclosed new heteroaromatic macrocyclic ether compounds acting as proto-oncogene tyrosine-protein kinase ROS (ROS1; MCF3) and/or ALK tyrosine kinase receptor inhibitors potentially useful for the treatment of cancer.

Bristol Myers Squibb Co. has identified tetrazole derivatives acting as diacylglycerol kinase α (DGK-α; DGKA) and/or diacylglycerol kinase ζ (DGK-ζ; DGKZ) inhibitors reported to be useful for the treatment of cancer and viral infections.

Suzhou Lexbio Pharm Co. Ltd. has patented macrocyclic triazole derivatives acting as high-affinity nerve growth factor receptor (NTRK1; TRKA) inhibitors reported to be useful for the treatment of cancer, multiple sclerosis, neuropathic pain, Alzheimer’s and Parkinson’s diseases.

Haisco Pharmaceutical Group Co. Ltd. has prepared proteolysis targeting chimera (PROTAC) compounds comprising a cereblon ligase-binding moiety coupled to an EGFR (HER1; erbB1)-targeting moiety through a linker.

Shanghai Jemincare Pharmaceuticals Co. Ltd. has disclosed nitrogen-containing heterocyclic compounds acting as ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors potentially useful for the treatment of cancer.

A Tibet Haisco Pharmaceutical Co. Ltd. patent describes new phosphodiesterase PDE4B inhibitors potentially useful for the treatment of cancer, chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis.

Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has identified new tricyclic compounds acting as GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

Cukurova University and the University of Alicante have synthesized new 2-(pyrrolidin-1-yl)thiazole compounds reported to be useful for the treatment of bacterial infections and tuberculosis.